Congratulations to Prof Michael Hofman and Team: ProPSMA trial
ARTnet would like to extend congratulations to Prof Michael Hofman and the team of investigators across Australia who were involved in the ProPSMA trial (Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy) which was published in the Lancet this week.
This prospective, multicentre study involved the collaboration of 10 Nuclear Medicine sites across Australia, and the results of this study will have international impact for the management of prostate cancer patients.
The study concluded that PSMA PET had greater accuracy than conventional imaging with bone scan and CT (92% vs 65% p<0.001).
There was a high reporter agreement for PSMA PET and management change occurred more frequently with PSMA PET imaging than conventional imaging.
To read the full article, please visit https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30314-7/fulltext.